A detailed history of Sws Partners transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Sws Partners holds 3,247 shares of VRTX stock, worth $1.68 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares
3,247
Previous 3,609 10.03%
Holding current value
$1.68 Million
Previous $1.69 Million 10.7%
% of portfolio
0.49%
Previous 0.51%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

SELL
$460.0 - $505.78 $166,520 - $183,092
-362 Reduced 10.03%
3,247 $1.51 Million
Q2 2024

Jul 17, 2024

SELL
$392.81 - $485.53 $289,500 - $357,835
-737 Reduced 16.96%
3,609 $1.69 Million
Q1 2024

Apr 30, 2024

SELL
$407.69 - $446.08 $22,830 - $24,980
-56 Reduced 1.27%
4,346 $1.82 Million
Q4 2023

Feb 13, 2024

SELL
$343.0 - $410.68 $24,696 - $29,568
-72 Reduced 1.61%
4,402 $1.79 Million
Q3 2023

Nov 09, 2023

SELL
$338.18 - $362.46 $376,732 - $403,780
-1,114 Reduced 19.94%
4,474 $1.56 Million
Q2 2023

Aug 17, 2023

BUY
$314.42 - $351.91 $1.76 Million - $1.97 Million
5,588 New
5,588 $1.97 Million
Q2 2023

Jul 26, 2023

SELL
$314.42 - $351.91 $18,865 - $21,114
-60 Reduced 1.06%
5,588 $1.97 Million
Q1 2023

May 09, 2023

BUY
$283.23 - $323.1 $1.6 Million - $1.82 Million
5,648 New
5,648 $1.78 Million
Q3 2022

Nov 09, 2022

BUY
$273.83 - $305.53 $7,667 - $8,554
28 Added 0.5%
5,592 $1.62 Million
Q2 2022

Jul 28, 2022

BUY
$234.96 - $292.55 $2,584 - $3,218
11 Added 0.2%
5,564 $1.57 Million
Q1 2022

May 05, 2022

SELL
$221.42 - $260.97 $952,991 - $1.12 Million
-4,304 Reduced 43.66%
5,553 $1.45 Million
Q4 2021

Jan 25, 2022

BUY
$177.01 - $223.45 $443,941 - $560,412
2,508 Added 34.13%
9,857 $2.17 Million
Q3 2021

Nov 08, 2021

BUY
$181.39 - $202.99 $24,487 - $27,403
135 Added 1.87%
7,349 $1.33 Million
Q2 2021

Aug 09, 2021

BUY
$187.49 - $221.1 $26,248 - $30,954
140 Added 1.98%
7,214 $1.46 Million
Q1 2021

May 17, 2021

BUY
$207.02 - $241.31 $680,888 - $793,668
3,289 Added 86.9%
7,074 $1.52 Million
Q4 2020

Mar 31, 2021

BUY
$207.01 - $276.09 $213,220 - $284,372
1,030 Added 37.39%
3,785 $895,000
Q3 2020

Nov 13, 2020

BUY
$255.65 - $303.1 $76,439 - $90,626
299 Added 12.17%
2,755 $750,000
Q2 2020

Aug 13, 2020

BUY
$225.48 - $295.8 $58,850 - $77,203
261 Added 11.89%
2,456 $668,000
Q1 2020

May 14, 2020

BUY
$199.77 - $247.81 $116,266 - $144,225
582 Added 36.08%
2,195 $522,000
Q3 2019

Nov 21, 2019

SELL
$166.23 - $187.09 $4.74 Million - $5.33 Million
-28,505 Reduced 94.64%
1,613 $337,000
Q3 2019

Nov 15, 2019

BUY
$166.23 - $187.09 $4.71 Million - $5.3 Million
28,327 Added 1581.63%
30,118 $5.27 Million
Q2 2019

Aug 13, 2019

BUY
$164.61 - $190.37 $63,210 - $73,102
384 Added 27.29%
1,791 $319,000
Q4 2018

Feb 04, 2019

SELL
$151.91 - $192.21 $20,052 - $25,371
-132 Reduced 8.58%
1,407 $233,000
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $258,136 - $296,626
1,539 New
1,539 $297,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Sws Partners Portfolio

Follow Sws Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sws Partners, based on Form 13F filings with the SEC.

News

Stay updated on Sws Partners with notifications on news.